Efficacy Study of Single Stage Breast Reconstruction in Female Participants With Mastectomy (ESSBR)

A Prospective, Multicenter, Controlled Study of Implant-based Breast Reconstruction, Measuring the Safety, Efficacy and Outcomes, of Immediate Single Stage Breast Reconstruction With Strattice™ Reconstructive Tissue Matrix Versus Immediate Two Stage Breast Reconstruction Without Strattice™ TM (ESSBR-Efficacy of Single Stage Breast Reconstruction)

The purpose of this study was to compare the efficacy of immediate single-stage post-mastectomy breast reconstruction with Strattice Reconstructive Tissue Matrix (Strattice) as compared to immediate two-stage post-mastectomy breast reconstruction where the initially placed expander was exchanged for a breast implant only, without any type of reinforcement.

Study Overview

• Status: Terminated
• Conditions: Mastectomy and Breast Reconstruction
• Intervention / Treatment: Procedure: Breast Reconstruction, Direct to Implant (DTI) with Strattice™; Procedure: Two Stage Breast Reconstruction

Detailed Description

The primary objective of this study is to compare the efficacy of immediate single-stage post-mastectomy breast reconstruction with Strattice™ TM, otherwise referred to as DTI as compared to immediate two-stage post-mastectomy breast reconstruction where the initially placed expander will be exchanged for a breast implant only, without any type of a reinforcement. The objective will be achieved by prospectively assessing the number of planned and unplanned post-mastectomy surgical interventions within 12 months of the mastectomy.

Two-stage breast reconstruction will include the initial placement of a tissue expander in a total or partial submuscular position. In the case of partial muscle coverage, this will be without the support of any mesh or autologous flap to reinforce the lower pole. The expander will be inflated over approximately the next one to six months, and then replaced with an implant.

• Study Type: Interventional
• Enrollment (Actual): 131
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33076
    • Institut Bergonié
  • Lille Cedex, France, 59000
    • Centre Oscar Lambret
  • Montpellier Cedex 5, France, 34298
    • Institut du Cancer de Montpellier Val d'Aurelle
  • Paris, France
    • Hôpital Tenon APHP
  • Paris, France, 75116
    • L'Institut du Sein- Paris Breast Center
• Germany
  • Erlangen, Germany, 91054
    • Universitätsklinikum Erlangen
  • Essen, Germany, 45131
    • Kliniken Essen-Mitte
  • Freiburg, Germany, 79106
    • Universitätsklinikum Freiburg
  • Hannover, Germany, 30625
    • Medizinische Hochschule Hannover
  • Heidelberg, Germany, 69115
    • Universitäts-Frauenklinik Heidelberg
  • Munich, Germany, 81675
    • Klinikum rechts der Isar
  • Munich, Germany, 80337
    • Klinik der Universität München, Campus Innenstadt
  • Wiesbaden, Germany, 65197
    • Asklepios Paulinen Klinik
• United Kingdom
  • Bradford, United Kingdom, BD5 0NA
    • St Luke's hospital / Bradford Royal Infirmary (BRI)
  • Dorchester, United Kingdom, DT1 2JY
    • Dorset County Hospital
  • Frimley, United Kingdom, GU16 7UJ
    • Frimley Park Hospital
  • Manchester, United Kingdom, M23 9LT
    • Wythenshawe Hospital UHSM NHS Foundation Trust
  • Nottingham, United Kingdom, NG5 1PB
    • City Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female 18 years or older
• A candidate for both arms of the study involving immediate breast reconstruction post-skin sparing mastectomy (unilateral or bilateral) DTI with the use of Strattice™ Reconstructive Tissue Matrix (TM), 2 stage with use of Tissue Expander through exchange to Implant without support of a mesh or autologous tissue)
• An American Society of Anesthesiologists (ASA) Physical Status Classification of 1 or 2
• Estimated life expectancy > 3 years
• Able and willing to return for all scheduled and required study visits
• Able to provide written informed consent for study participation

Exclusion Criteria:

• Clinically significant systemic disease, as determined by the Investigator, which could affect study participation or study results
• Received neo-adjuvant, inductive chemo-therapy (except Herceptin, or other targeted therapy) within 4 weeks prior to mastectomy
• Previous radiation therapy to either breast at any time
• Predicted permanent implant size that is greater than or equal to 500 grams (gms), per Investigator assessment
• Body mass index (BMI) <17 or > 30
• Co-morbid factors which predispose to postoperative infection, e.g. diabetes, collagen vascular disease, chronic steroid (except inhalers)/immunosuppressant use, immune deficiency, or co-existent infection
• Pregnant or lactating
• 3rd degree ptosis
• Prior breast surgery including breast reduction, augmentation, mastopexy, quadrectomy, and partial mastectomy with reduction of the skin envelope
• Prior use of a device (mesh or matrix) in the Breast
• Concomitant unrelated condition of breast/chest wall/skin that, as determined by the investigator, could adversely affect the surgical outcome (e.g. significant chest wall abnormalities including pectus excavatum or pectus carinatum)
• Planned autologous tissue flap in addition to prosthetic implant
• Use of permanent expander implants such as Becker expanders or the Natrelle™ Permanent expander 150
• Current alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or drug abuse or addiction
• Currently enrolled or plans to enroll in another clinical trial unless it is: a registry, a retrospective study, a neo-adjuvant chemotherapy trial (as long as the chemotherapy regimen has been stopped 4 weeks prior to mastectomy), or a hormone/anti-hormonal therapy trial
• Any of the conditions identified within the labelled contraindications, i.e. sensitivity to porcine derived products or polysorbate 20.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Breast Reconstruction, Direct to Implant (DTI) with Strattice™; Participants underwent immediate post-mastectomy breast reconstruction with a breast implant and Strattice™ reconstructive tissue matrix (surgical mesh).	Procedure: Breast Reconstruction, Direct to Implant (DTI) with Strattice™
Active Comparator: Two Stage Breast Reconstruction; Participants underwent immediate, two-stage post-mastectomy breast reconstruction without reinforcement. Initial placement of a tissue expander that was inflated for approximately one to six months, and then replaced with an implant.	Procedure: Two Stage Breast Reconstruction

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Number of Planned and Unplanned Post-mastectomy Surgical Interventions Per Participant on the Reconstructed Breast, Within 12 Months of the Initial Study Surgery (ISS)	ISS was defined as the DTI breast reconstruction with Strattice™ or the first surgery of the two-stage breast reconstruction. Data is presented for participants with unilateral (one breast) and bilateral (two breast) reconstruction. Postmastectomy surgical interventions on the reconstructed breast were reported for each participant and the total number of planned and unplanned post-mastectomy surgical interventions was averaged in each group.	Up to 12 months post ISS

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Experiencing One or More Serious Breast Reconstruction-related Complications (BRRC)	Serious BRRC were complications that required re-entry of the breast pocket with or without exchange or removal of the implant and any manipulation of the implant pocket including the infra-mammary fold (IMF). Serious BRRC were detected through review by a medical monitor. Surgical complications included: capsular contracture (Baker grade ≥ 3), infection (local or systemic), hematoma, seroma, inflammation, skin or flap necrosis, implant extrusion, malposition, malrotation, asymmetry, bottoming out.	Up to 12 months post ISS
Number of Participants Experiencing One or More Serious BRRC Within 24 Months of Post-Permanent Reconstruction (ppR)	Serious BRRC were complications that required re-entry of the breast pocket with or without exchange or removal of the implant and any manipulation of the implant pocket including the IMF. Serious BRRC were detected through review by a medical monitor. BRRC were defined as: a) infection, local or systemic, b) hematoma, c) seroma, d) inflammation, e) skin or flap necrosis, f) capsular contraction as defined by Baker grade > 3, g) implant extrusion (loss or explants), and h) malposition, malrotation, asymmetry, and bottoming out.	Up to 24 months ppR
Number of Participants With Clinically Significant Cases of Capsular Contracture as Defined by Baker Grade III or IV Within 24 Months of ppR	The surgeon assessed the level of capsular contracture in the participant's breast using the Baker Breast Contracture Scale where: Grade I=breast is normally soft and looks natural, Grade II=breast is a little firm but looks normal, Grade III=breast is firm and looks abnormal and Grade IV= breast is hard, painful, and looks abnormal. Baker Grade III and IV were defined as clinically significant and are reported here. Data is presented for number of participants with capsular contracture per breast (right breast and left breast).	Up to 24 months ppR
Aesthetic Outcomes of Participants Using Blinded Assessment 2D Photographs by Independent Review Panel		Baseline up to Month 24
Number of Planned and Unplanned Post-mastectomy Surgical Interventions of the Reconstructed Breast Within 6 Months of ISS	ISS was defined as the DTI breast reconstruction with Strattice™ or the first surgery of the two-stage breast reconstruction. Data is presented for participants with unilateral (one breast) and bilateral (two breast) reconstruction. Postmastectomy surgical interventions on the reconstructed breast were reported for each participant and the total number of planned and unplanned post-mastectomy surgical interventions was averaged in each group.	Baseline up to 6 months post ISS
Number of Planned and Unplanned Post-mastectomy Surgical Interventions of the Reconstructed Breast	Surgical interventions were all planned and unplanned post-mastectomy surgical interventions per participant on the reconstructed breast, within 24 months of the ISS, which is defined as the DTI breast reconstruction with Strattice™ TM or the first surgery of the two-stage breast reconstruction. Data is presented for participants with unilateral (one breast) and bilateral (two breast) reconstruction.	Within 24 months ppR

Other Outcome Measures

Outcome Measure	Time Frame
Health-related Quality of Life	At 3, 6, and 12 months post-mastectomy and at 4 months ppR
Healthcare Resource Use Including Length of Hospital Stay and Clinic Visits	At 6 and 12 months post-mastectomy and at 24 months ppR
Time to Return to Work or Normal Daily Activities	6 and 12 months post-mastectomy and 24 month ppR

Collaborators and Investigators

• Sponsor: LifeCell
• Investigators: Study Chair: Donna Jacobs, Allergan

Study record dates

Study Major Dates

• Study Start (Actual): July 29, 2013
• Primary Completion (Actual): August 31, 2016
• Study Completion (Actual): October 23, 2017

Study Registration Dates

• First Submitted: July 22, 2013
• First Submitted That Met QC Criteria: July 25, 2013
• First Posted (Estimate): July 29, 2013

Study Record Updates

• Last Update Posted (Actual): December 4, 2019
• Last Update Submitted That Met QC Criteria: November 14, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Keywords: Breast cancer; Breast reconstruction; Mastectomy; Breast implant
• Other Study ID Numbers: LFC 2012.06.01